What a surprise. Virax is having another capital raising. This makes 11 in 10 years, while the proposed raising on the UK AIM market will make it 12 in 10 years. Most junior biotechs have few capital raisings and frequent positive announcements. Virax, on the other hand, has frequent capital raisings while rarely having good news. I wonder if this has something to do with the company's woeful performance. Unfortunately, management have never had the sense to raise anywhere remotely near enough capital for the tasks at hand.
Add to My Watchlist
What is My Watchlist?
